Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis:A case report and literature review  

作　　者：Dan Pan Tai-Ping Li Jian-Hui Xiong Shu-Bo Wang Yao-Xu Chen Jian-Feng Li Qi Xiao 

机构地区：[1]Department of General Surgery,The First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China [2]The Medical Department,3D Medicines Inc.,Shanghai 201114,Shanghai Province,China

出　　处：《World Journal of Clinical Cases》2022年第9期2818-2828,共11页世界临床病例杂志

基　　金：Supported by the Natural Science Foundation of Jiangxi Province (No. 20192BAB215012 and No. 20212BAB206027);the Health Commission of Jiangxi Province (No. 20203206)

摘　　要：BACKGROUND Primary splenic angiosarcoma(PSA)is an extremely rare and aggressive mesenchymal malignancy with high metastatic potential and a poor prognosis.There are no established treatment guidelines for PSA,even for adjuvant therapy.This rare case may provide a reliable therapeutic regime for a better prognosis.CASE SUMMARY A 49-year-old female who complained of right-upper quadrant abdominal pain was diagnosed as having PSA with splenic rupture and liver metastasis.After splenectomy and liver tumor resection,she received sorafenib and camrelizumab therapy.After 15 mo of follow-up,she is in good condition,without recurrence or any identified metastasis.CONCLUSION Immunotherapy combined with targeted therapy could be a potential option for the adjuvant therapy of PSA.

关 键 词：Primary splenic angiosarcoma Immunotherapy Targeted therapy Prognosis Case report 

分 类 号：R733.2[医药卫生—肿瘤]